Document Type : Original Article(s)
Authors
1
Assistant Professor of Hematology & Oncology Department of Internal Medicine, School of Medicine "Cancer Research Center Shahrekord University of Medical Sciences " Hajar Hospital Shahrekord University of Medical Science
2
Assistant Professor of Hematology & Oncology Department of Internal Medicine, School of Medicine Cancer Prevention Research Center Seyyed Al-Shohada Hospital Isfahan University of Medical Sciences
3
Associate Professor of Hematology & Oncology Department of Internal Medicine, School of Medicine Cancer Prevention Research Center Seyyed Al-Shohada Hospital Isfahan University of Medical Sciences
4
Professor of Hematology & Oncology Department of Internal Medicine, School of Medicine Cancer Prevention Research Center Seyyed Al-Shohada Hospital Isfahan University of Medical Sciences
5
Professor of Community Medicine Department of Community and Family Medicine, School of Medicine Child Growth and Development Research Center Research Institute for Primordial Prevention of Non-communicable Disease Isfahan University of Medical Scienc
10.48305/jims.2026.45480.2579
Abstract
Background: Due to the unavailability of BCNU in countries like Iran, alternatives are being explored. This study compares chemotherapy regimens including Carboplatin versus CCNU as pre-transplant conditioning for refractory/relapsed lymphoma at Seyed-al-Shohada Hospital.
Methods: This non-randomized clinical trial included patients hospitalized for autologous stem cell transplantation(ASCT) due to relapsed/refractory lymphoma at Hospital. Patients treated between 2016 and October 2018 received regimen A(Carboplatin, Etoposide, ARAC, Melfalan, 23 patients), while those treated from October 2018 to 2021 received regimen B(CCNU, Etoposide, ARAC, Melfalan, 25 patients). Data on demographics, disease status, and post-transplant outcomes were analyzed by SPSS version 22.
Results: Overall survival(OS) was 32.47 ± 10.41 months for group A and 34.40 ± 4.65 months for B. Progression-free survival(PFS) was 28.47 ± 13.51 months for group A and 26.87 ± 11.99 for B(P=0.071). The average hospitalization for group A was 21.39±4.08 days and 17.72 ± 1.59 days for B (P=0.0001). The time to engraftment was 12.55 ± 2.92 days for group A and 11.56 ± 1.32 for B (P=0.253). Duration of neutropenia for group A was 9.82 ± 3.14 days and for group B was 8.80 ± 1.87 days (P=0.290). Duration of antibiotic treatment for group A was 9.33 ± 3.23 days and for group B was 6.28 ± 1.74 days (P=0.0001). Mortality was 17.4% (4 patients) in group A and 12% (3 patients) in group B.
Conclusion: Carboplatin is a viable alternative to CCNU in the BEAM regimen before ASCT.
Keywords:, autologous stem cell transplantation, lymphoma, BEAM.
Highlights
Alireza Sadeghi: Google Scholar
Yaser Salehi: Google Scholar
Keywords
Subjects
